Allianz Asset Management AG lowered its stake in shares of Advaxis, Inc. (NASDAQ:ADXS) by 14.4% during the fourth quarter, Holdings Channel reports. The institutional investor owned 146,927 shares of the biotechnology company’s stock after selling 24,777 shares during the period. Allianz Asset Management AG’s holdings in Advaxis were worth $1,052,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors also recently made changes to their positions in ADXS. Koshinski Asset Management Inc. bought a new position in shares of Advaxis during the third quarter valued at $156,000. Fox Run Management L.L.C. bought a new position in shares of Advaxis during the third quarter valued at $175,000. Northern Capital Management LLC boosted its position in shares of Advaxis by 6.0% in the third quarter. Northern Capital Management LLC now owns 18,125 shares of the biotechnology company’s stock valued at $194,000 after buying an additional 1,025 shares in the last quarter. Creative Planning boosted its position in shares of Advaxis by 2.8% in the third quarter. Creative Planning now owns 30,100 shares of the biotechnology company’s stock valued at $322,000 after buying an additional 820 shares in the last quarter. Finally, SG Americas Securities LLC bought a new position in shares of Advaxis during the third quarter valued at $418,000. Institutional investors own 57.42% of the company’s stock.
Shares of Advaxis, Inc. (NASDAQ:ADXS) opened at 8.51 on Tuesday. The stock has a 50 day moving average price of $8.93 and a 200-day moving average price of $9.24. Advaxis, Inc. has a 52-week low of $6.47 and a 52-week high of $16.30. The stock’s market capitalization is $342.91 million.
Several research analysts recently weighed in on the company. HC Wainwright set a $23.00 price target on Advaxis and gave the company a “buy” rating in a research report on Tuesday, January 17th. Cantor Fitzgerald reiterated a “buy” rating and set a $19.00 price target on shares of Advaxis in a research report on Monday, February 27th. Five investment analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and a consensus price target of $24.00.
In other news, CFO Sara Bonstein sold 5,520 shares of the stock in a transaction dated Friday, December 30th. The stock was sold at an average price of $7.37, for a total value of $40,682.40. Following the transaction, the chief financial officer now owns 131,963 shares in the company, valued at approximately $972,567.31. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 4.56% of the company’s stock.
Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.
Want to see what other hedge funds are holding ADXS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Advaxis, Inc. (NASDAQ:ADXS).